Northwest & Ethical Investments L.P. Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Northwest & Ethical Investments L.P. increased its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 209.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 43,466 shares of the company's stock after purchasing an additional 29,398 shares during the quarter. Northwest & Ethical Investments L.P.'s holdings in Moderna were worth $1,807,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new position in shares of Moderna during the 3rd quarter worth about $377,000. Empowered Funds LLC increased its stake in Moderna by 6.6% during the 3rd quarter. Empowered Funds LLC now owns 5,199 shares of the company's stock worth $347,000 after buying an additional 322 shares in the last quarter. Quest Partners LLC raised its holdings in shares of Moderna by 239.8% during the third quarter. Quest Partners LLC now owns 4,567 shares of the company's stock valued at $305,000 after acquiring an additional 3,223 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Moderna in the third quarter valued at approximately $1,515,000. Finally, Commerce Bank boosted its stake in shares of Moderna by 9.1% in the third quarter. Commerce Bank now owns 9,471 shares of the company's stock worth $633,000 after acquiring an additional 787 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Analysts Set New Price Targets

MRNA has been the subject of a number of analyst reports. JPMorgan Chase & Co. dropped their price target on Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Friday. Citigroup assumed coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price for the company. Argus cut shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Bank of America cut their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Finally, UBS Group decreased their target price on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $59.00.

Remove Ads

Moderna Stock Performance

Moderna stock traded up $1.71 during midday trading on Monday, hitting $34.37. 6,783,335 shares of the company's stock were exchanged, compared to its average volume of 6,632,066. The stock has a market cap of $13.26 billion, a price-to-earnings ratio of -3.70 and a beta of 1.86. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47. The firm's 50 day simple moving average is $34.91 and its 200 day simple moving average is $45.67.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.